Erschienen in:
01.10.2004 | Original Article
TiA1 in advanced-stage classical Hodgkin’s lymphoma: no prognostic impact for positive tumour cells or number of cytotoxic cells
verfasst von:
Sophie Camilleri-Broët, Christophe Fermé, Françoise Berger, Eric Lepage, Serge Bain, Josette Brière, Béatrice Marmey, Philippe Gaulard, Josée Audouin
Erschienen in:
Virchows Archiv
|
Ausgabe 4/2004
Einloggen, um Zugang zu erhalten
Abstract
No reliable marker still exists for predicting those patients with Hodgkin’s lymphoma (HL) who may experience a fatal outcome. Among the factors tested in the literature, it has been suggested that the number of activated cytotoxic T cells may represent a prognostic marker in HL. In 244 samples from patients with stage-IIIB/IV HL issued from the GELA H89 trial, we have analysed TiA1 expression on Reed Sternberg (RS) cells as well as the percentage of positive reactive lymphocytes. There were 34 cases (13.7%) that showed TiA1 expression on tumour cells; whereas, in 32 cases (13.1%), TiA1-positive reactive lymphocytes represented more than 30% of the reactive lymphocytes. LMP-1 was found co-expressed with TiA1 in 10 of the 22 positive cases tested. Our study confirms that a subset of classical HL expresses cytotoxic proteins, with occasional co-expression of CD20. In stage-IIIB/IV disease, neither TiA1 expression by RS cells nor a high percentage of TiA1-positive reactive lymphocytes have a prognostic impact on outcome.